Navigation Links
Nurses Can Play Big Role In Helping Patients Quit Smoking

Nurses who advice patients to give up smoking may be more successful than anyone else in helping patients kick the habit, according to a new study in the July-August 2006// Nursing Research journal. "These reports are evidence that nurses are widely recognized as central to global efforts to reduce the detrimental health effects of tobacco use," said Dr. Molly C. Dougherty, Nursing Research editor and professor of nursing at the University of North Carolina at Chapel Hill.

The Nursing Research articles contain tobacco cessation information including original research evaluating methods for treating tobacco dependence. For example, one study found that smokers who received tobacco cessation information from their nurses were nearly 50 percent more likely to quit than smokers with no nursing intervention. The report also notes that nurses often care for underserved people, who are disproportionately affected by tobacco use.

Summaries in the journal highlight innovative methods for treating tobacco dependence and practical approaches for clinical use, including recommendations from 42 researchers, clinicians, educators and representatives from the Agency for Healthcare Research and Quality and the National Cancer Institute.

"This information represents a call to action for nurses, health care providers and policy-makers. Health care professionals, and particularly nurses, have tremendous access to patients and families affected by tobacco use. Nurses are in the unique position to act as agents of change when it comes to preventing and treating tobacco dependence," Dougherty said.

Nurses - the largest group of health care professionals - can have an expanded impact on tobacco cessation, the report says. To treat tobacco dependence, researchers recommended widespread training of nurses to deliver interventions to patients. They also recommended examining the prevalence of smoking among health care providers themselves, citi
'"/>




Page: 1 2

Related medicine news :

1. Nurses save more lives
2. Nurses competing with junior doctors in some assessments
3. Nurses In Ontario demands Safe Disposable Needles
4. School Children Put To Risk Due To Shortage Of Nurses
5. Flu Shots Not Mandatory For Nurses
6. Mummy Is Always Right: Nurses Research Prove It Over Again
7. Kerala To Become Testing Center For US Bound Nurses
8. South Africa To Recruit Indian Nurses
9. Nursing A Threat : NHS Nurses May Stage A Royal Protest
10. Doctors Protest Against Allowing Nurses To Perform Minor Surgeries
11. Nurses Help Sought To Check Teenage Pregnancies In English Schools
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...sure levels that tend to be slightly elevated but ...d high-normal--are at increased risk for suffering...aken in two numbers. The systolic value i.e., the ...resents the pressure in the heart during contracti...
...trol pills should be mindful of the possible inter...ions recommended by the Federal Centers for Diseas...he CDC recently recommended that antibiotic and an...ine, and penicillin, be used to treat those believ...
...through, a team of scientists have successfully tr...e to the diseased one, bringing light to the peopl...ning the current excitement about stem cells, in a...uch as chemical burns, allergic reactions to drug ...
...n acrylic cement mend fractures linked to osteopor...the University of California have been looking at ...res in 90 elderly patients with osteoporosis. They...a - a procedure formerly done during surgery. Two ...
Other Medicine News:
(Date:9/3/2008)...ease Awareness Month, CHARLOTTESVILLE, Va., Sept....a clinical-stage drug-development company commerci...al needs, announced today that it has begun,to enr... lead drug,candidate trans sodium crocetinate (TSC...altrials.gov Website, is investigating TSC as a tr...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...lans with FDA, PRINCETON, N.J., Sept. 3 /PRNewswi...hat it successfully completed two key clinical tri...ative low-dose, once-weekly,contraceptive patch, ...t,code AG-200-15. The Phase 2b safety and efficacy...ulation suppression, cycle control and safety. The...
(Date:9/3/2008)...nce Pycnogenol(R) Lowers Joint, Pain, Symptoms; Ma...ation of the Extract, ...to the Center for,Disease Control (CDC), osteoarth...e rise. A new study published in the August journa... bark extract from the French maritime pine,tree, ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 1Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 2Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 3Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 4Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 5New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 1New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 2
... WIRE)--May 1, 2007 - Teva,Pharmaceutical Industri... data from a 36-week, randomized, double-blind,pl... an oral 0.6 mg,dose of laquinimod given daily sig...) disease activity by 38 percent in RRMS,patients ...avorable,trend towards reducing annual relapse rat...
...isease Activity as Measured,by MRI and Relapse --...nc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BII...inical study of Rituxan®,(rituximab) in patien...MS) were presented today at the American Academy o... is a therapeutic antibody,that targets and select...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ic stools come with five legs for extra stability....ical travel 6"). 2" ball bearing swivel hard rubbe... upholstery, available in black vinyl as standard,... a contoured, padded, upholstered backrest, with v...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Medicine Products: